Objective: Aflibercept increased overall survival with acceptable tolerability in metastatic
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …

Purpose In the VELOUR study, aflibercept+ FOLFIRI regimen resulted in improved survival
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …

Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular
endothelial growth factor (VEGF), a key regulator of angiogenesis. It binds to all isoforms of …

Background Although no data have been reported beyond second-line therapy, aflibercept
is approved in this setting in many countries. We conducted a multicenter study to analyze …

Introduction Anti-angiogenic drugs are an efficacious class of therapy in the treatment of
patients with metastatic colorectal cancer (mCRC). Aflibercept, a vascular endothelial growth …

Background Safety and effectiveness of aflibercept with 5‐fluorouracil/levofolinate/irinotecan
have not been reported in Japanese patients with metastatic colorectal cancer (mCRC) in a …

Background The objectives of this study were to evaluate the safety profile of aflibercept and
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …

Experience with aflibercept as a second line chemotherapy in metastatic colorectal cancer:
Safety and efficacy in a real-life po Page 1 of Epidemiology and Biostatistics, University of Tokyo …

Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden
globally and an increasing challenge in Asian countries. Treatment options include …

Abstract Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept
improves median overall survival (OS) and progression-free survival (PFS) in patients with …